
## Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



LTBI: Latent TB Infection
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme









## Pediatric Latent TB Infection Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (LTBI '18)	WHO Guidelines (LTBI '20)	EMLcsubmitted	EMLc (2019)	WHO PQ EOI (2020)	WHO PQ submitted	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Mar 2020)	Global Fund ERP approved	GDF Catalog
Rifampicin/Isoniazid 75/50 dispersible tablet											
Rifapentine 150mg dispersible tablet											
Rifapentine 300mg scored, dispersible											
Rifapentine/Isoniazid 150mg/150mg dispersible tablet											
Rifapentine/Isoniazid 300mg/300mg dispersible tablet											
Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 400/80/150/ 12.5mg tablet											

LTBI: Latent TB Infection
EML: Essential Medicines List
EOI: Expression of Interest

**ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme







Status
Yes
No

N/A

Ineligible for inclusion

